Pharmacogenetics to Predict Drug-Related Adverse Events

Abstract

Identification of reliable markers to predict drug-related adverse events (DRAEs) is an important goal of the pharmaceutical industry and others within the healthcare community. We have used genetic polymorphisms, including the most frequent source of variation (single nucleotide polymorphisms, SNPs) in the human genome, in pharmacogenetic approaches designed to predict DRAEs. Three studies exemplify the principles of using polymorphisms to identify associations in progressively larger genomic regions: polymorphic repeats within the UDP-glucuronysltransferase I (UGT1A1) gene in patients experiencing hyperbilirubinemia after administration of tranilast, an experimental drug to prevent re-stenosis following coronary revascularization; high linkage disequilibrium within the Apolipoprotein E (ApoE) gene in patients with Alzheimer Disease (AD); and the polymorphic variant HLA-B57 in patients with hypersensitivity reaction after administration of abacavir, a nucleoside reverse transcriptase inhibitor for the treatment of HIV. Together, these studies demonstrate in a stepwise manner the feasibility of using pharmacogenetic approaches to predict DRAEs.

Keywords

Pharmacogenetics adverse drug reaction drug-related adverse event single nucleotide polymorphism Gilbert's syndrome Tranilast Apolipoprotein E Alzheimer's Disease abacavir hypersensitivity reaction.

References

Bosma, P.

Chowdhury, J.R.

Bakker, C.

Gantla, S.

de Boer, A.

Oostra, B.A.

Lindhout, D.

Tytgat, G.N.

Jansen, P.L.

, and

Oude Elferink, R.P.

(1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Eng J Med333, 1171—5.

Bosma, P.

Chowdhury, N.R.

Goldhoorn, B.G.

Hofker, M.H.

Oude Elferink, R.P.

Jansen, P.L.

, and

Chowdhury, J.R.

(1992). Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology15: 941—7.

Haramburu, F.

Pouyanne, P.

Imbs, J.L.

Blayac, J.P.

, and

Begaud, B.

(2000). Incidence and prevalence of adverse drug reactions . Presse Medicale29, 111—4.

Hetherington, S.

Hughes, A.R.

Mosteller, M.

Shortino, D.

Baker, K.L.

Spreen, W.

Lai, E.

Davies, K.

Handley, A.

Dow, D.J.

Fling, M.E.

Stocum, M.

Bowman, C.

Thurmond, L.M.

, and

Roses, A.D.

(2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet359, 1121—2.

Hetherington, S.

McGuirk, S.

Powell, G.

Cutrell, A.

Naderer, O.

Spreen, B.

Lafon, S.

Pearce, G.

, and

Steel, H.

(2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther23, 1603—14.

Lai, E.

Riley, J.

Purvis, I.

, and

Roses, A.

(1998). A 4-Mb high-density single nucleotide polymorphism-based map around ApoE. Genomics54, 31—8.

Mallal, S.

Nolan, D.

Witt, C.

Masel, G.

Martin, A.M.

Moore, C.

Sayer, D.

Castley, A.

Mamotte, C.

Maxwell, D.

James, I.

, and

Christiansen, F.T.

(2002). Lancet359, 727—32.

Melton, L.

(2003). On the trail of SNPs. Nature422, 917—23.

Rigby, K.D.

, and

Litt, J.C.

(2000). Errors in health care management: what do they cost? Qual Health Care9, 216—21.

10.

Roses, A.D.

(2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev1, 541—9.

11.

Saunders, A.M.

Strittmatter, W.J.

Schmechel, D.

St George-Hyslop, P.H.

Pericak-Vance, M.A.

Joo, S.H.

Rosi, B.L.

Gusella, J.F.

Crapper-MacLachlan, D.R.

Alberts, M.J.

, and

Roses, A.D.

(1993). Association of apolipoprotein E allele E4 with late-onset familial and sporadic alzheimer disease. Neurology43, 1467—72.

12.

Schenkel, S.

(2000). Promoting patient safety and preventing medical error in emergency departments. Acad Emer Med7, 1204—22.

13.

Schioler, T.

Lipczak, H.

Pedersen, B.L.

Mogensen, T.C.

Bach, K.B.

Stockmarr, A.

Svenning, A.R.

, and

Frolich, A.

(2001). Incidence of adverse events in hospitals. A retrospective study of medical records. U Laeger163, 5370—8.

14.

Strittmatter, W.J.

Saunders, A.M.

Schmechel, D.

Pericak-Vance, M.

Enghild, J.

Salvesen, G.S.

, and

Roses, A.D.

(1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial alzheimer disease. Proc Natl Acad Sci USA90, 1977—81.

15.

Thomas E.J.

Studdert, D.M.

Runciman, W.B.

Webb, R.K.

Sexton, E.J.

Wislon, R.M.

Gibberd, R.W.

Harrison, B.T.

, and

Brennan, T.A.

(2000). A comparison of iatrogenic injury studies in australia and the USA. I. Context, methods, casemix, population, patient and hospital characteristics. Int J Qual Health Care12, 371—8.